# Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis

> **NCT02794467** · PHASE2 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Adenomyosis

## Interventions

- **DRUG:** Epelsiban
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02794467
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-07
- **Primary completion:** 2016-10
- **Final completion:** 2016-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was prematurely discontinued due to GSK's change in prioritization for the portfolio and is not due to any safety concerns or regulatory interaction.
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02794467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02794467, "Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02794467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*